Literature DB >> 9931334

Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading.

D H Gutmann1, L Sherman, L Seftor, C Haipek, K Hoang Lu, M Hendrix.   

Abstract

The neurofibromatosis 2 ( NF2 ) gene product, merlin, is a tumor suppressor protein mutated in schwanno-mas and several other tumors. Merlin, which shares significant homology with the actin-associated proteins ezrin, radixin and moesin (ERM proteins), inhibits cell growth when overexpressed in cell lines. The similarities between merlin and ERM proteins suggest that merlin's growth-regulatory capabilities may be due to alterations in cytoskeletal function. We examined this possibility in rat schwannoma cell lines overexpressing wild-type merlin isoforms and mutant merlin proteins. We found that overexpression of wild-type merlin resulted in transient alterations in F-actin organization, cell spreading and cell attachment. Merlin overexpression also impaired cell motility as measured in an in vitro motility assay. These effects were only observed in cells overexpressing a merlin isoform capable of inhibiting cell growth and not with mutant merlin molecules (NF2 patient mutations) or a merlin splice variant (isoform II) lacking growth-inhibitory activity. These data indicate that merlin may function to maintain normal cytoskeletal organization, and suggest that merlin's influence on cell growth depends on specific cytoskeletal rearrangements.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931334     DOI: 10.1093/hmg/8.2.267

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.

Authors:  Raj Kishore; Gangjian Qin; Corinne Luedemann; Evelyn Bord; Allison Hanley; Marcy Silver; Mary Gavin; Young-sup Yoon; David Goukassian; David Goukassain; Douglas W Losordo
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

3.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

4.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.

Authors:  Rong Rong; Xiaoling Tang; David H Gutmann; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

5.  Brain Tumors in Neurofibromatosis.

Authors:  Deborah R. Gold; Bruce H. Cohen
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 6.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

7.  Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Authors:  Hansoo Lee; Donghwa Kim; Han C Dan; Eric L Wu; Tatiana M Gritsko; Chuanhai Cao; Santo V Nicosia; Erica A Golemis; Wanguo Liu; Domenico Coppola; Steven S Brem; Joseph R Testa; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

8.  Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants.

Authors:  Lorena B Benseñor; Kari Barlan; Sarah E Rice; Richard G Fehon; Vladimir I Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 9.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

10.  NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.

Authors:  E E Bosco; Y Nakai; R F Hennigan; N Ratner; Y Zheng
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.